EPISODE · Apr 21, 2025 · 46 MIN
Breaking Down Pharma in the Current Environment
from FDA Watch
Shelly and Wayne chat with Dr. Michelle McMurry-Heath, Founder and CEO of BioTechquity Clinical, and Alan Minsk, Partner, Chair of the Food & Drug practice, and Co-Chair of the Life Sciences industry team at Arnall Golden Gregory LLP. You'll hear their thoughts on the potential effects that FDA staffing cuts may have on drug and biologics approvals; how the current environment may affect investments in drug and biotech development; what companies can do to amid agency staffing shortages; how FDA can aim to include all demographics of patients in trials; and much more. In our headlines segment, Shelly and Wayne delve into these major developments: Pharma: Trump administration makes exception for pharmaceuticals amid rollout of tariffs Devices: Industry continues to face the consequences of cutbacks at CDRH Food: Food company completes FDA pre-market consultation for human food made with cultured pork fat cells Cosmetics: PCPC executive issues statement on impact of Trump administration's reciprocal tariffs on cosmetics and personal care products industry In our Resource Links segment, we list key documents in our four core areas. To view these links, subscribe, or find out more information about our podcast, visit FDAWatch.net. Want to be a sponsor, marketing partner, or guest, or provide feedback on the podcast? Email us at [email protected]. Music by Dvir Silver from Pixabay.
NOW PLAYING
Breaking Down Pharma in the Current Environment
No transcript for this episode yet
Similar Episodes
Feb 26, 2026 ·51m
Feb 25, 2026 ·3m
Feb 25, 2026 ·5m
Feb 25, 2026 ·27m